(PRVA) Privia Health - Overview
Stock: Physician, Technology, Population Health, Management Services, Accountable Care
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 35.4% |
| Relative Tail Risk | -5.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.22 |
| Alpha | -16.73 |
| Character TTM | |
|---|---|
| Beta | 0.556 |
| Beta Downside | 0.098 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.24% |
| CAGR/Max DD | -0.15 |
Description: PRVA Privia Health January 14, 2026
Privia Health Group, Inc. (NASDAQ: PRVA) is a national physician-enablement firm that partners with independent practices, health plans, and health systems to streamline clinical operations and accelerate value-based care adoption. Its core offerings include a technology platform for workflow optimization, a management-services organization that offloads administrative burdens, and a single-TIN medical group that consolidates negotiating leverage, clinical integration, and financial alignment.
In FY 2023 the company reported revenue of approximately $1.3 billion, with a year-over-year growth rate of roughly 12 % driven largely by expanding accountable-care organization (ACO) contracts and increased enrollment in its network-based payer solutions. Key sector drivers-rising Medicare Advantage participation, heightened emphasis on population health management, and the broader industry shift toward bundled-payment models-are expected to sustain demand for Privia’s integrated services. The firm’s operating margin improved to 5.8 % as it leveraged scale efficiencies across its technology and management services.
For a deeper, data-focused look at PRVA’s valuation and risk profile, consult the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 18.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.06 > 1.0 |
| NWC/Revenue: 19.00% < 20% (prev 21.81%; Δ -2.81% < -1%) |
| CFO/TA 0.08 > 3% & CFO 110.7m > Net Income 18.2m |
| Net Debt (-435.1m) to EBITDA (42.0m): -10.37 < 3 |
| Current Ratio: 1.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.8m) vs 12m ago 2.41% < -2% |
| Gross Margin: 9.91% > 18% (prev 0.10%; Δ 981.1% > 0.5%) |
| Asset Turnover: 163.6% > 50% (prev 149.8%; Δ 13.81% > 0%) |
| Interest Coverage Ratio: -5.76 > 6 (EBITDA TTM 42.0m / Interest Expense TTM -5.71m) |
Altman Z'' 1.37
| A: 0.29 (Total Current Assets 970.9m - Total Current Liabilities 582.9m) / Total Assets 1.35b |
| B: -0.12 (Retained Earnings -165.5m / Total Assets 1.35b) |
| C: 0.03 (EBIT TTM 32.9m / Avg Total Assets 1.25b) |
| D: -0.28 (Book Value of Equity -164.2m / Total Liabilities 588.2m) |
| Altman-Z'' Score: 1.37 = BB |
Beneish M -2.88
| DSRI: 1.03 (Receivables 499.0m/409.0m, Revenue 2.04b/1.72b) |
| GMI: 0.99 (GM 9.91% / 9.78%) |
| AQI: 1.11 (AQ_t 0.28 / AQ_t-1 0.25) |
| SGI: 1.19 (Revenue 2.04b / 1.72b) |
| TATA: -0.07 (NI 18.2m - CFO 110.7m) / TA 1.35b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of PRVA shares?
Over the past week, the price has changed by -5.95%, over one month by -10.89%, over three months by -14.03% and over the past year by -8.00%.
Is PRVA a buy, sell or hold?
- StrongBuy: 14
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.3 | 45.3% |
| Analysts Target Price | 31.3 | 45.3% |
| ValueRay Target Price | 20.9 | -3% |
PRVA Fundamental Data Overview February 03, 2026
P/E Forward = 24.6914
P/S = 1.3983
P/B = 4.0285
Revenue TTM = 2.04b USD
EBIT TTM = 32.9m USD
EBITDA TTM = 42.0m USD
Long Term Debt = 6.24m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.56m USD (from shortTermDebt, last quarter)
Debt = 6.24m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -435.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.42b USD (2.86b + Debt 6.24m - CCE 441.4m)
Interest Coverage Ratio = -5.76 (Ebit TTM 32.9m / Interest Expense TTM -5.71m)
EV/FCF = 22.11x (Enterprise Value 2.42b / FCF TTM 109.5m)
FCF Yield = 4.52% (FCF TTM 109.5m / Enterprise Value 2.42b)
FCF Margin = 5.36% (FCF TTM 109.5m / Revenue TTM 2.04b)
Net Margin = 0.89% (Net Income TTM 18.2m / Revenue TTM 2.04b)
Gross Margin = 9.91% ((Revenue TTM 2.04b - Cost of Revenue TTM 1.84b) / Revenue TTM)
Gross Margin QoQ = 10.51% (prev 9.15%)
Tobins Q-Ratio = 1.79 (Enterprise Value 2.42b / Total Assets 1.35b)
Interest Expense / Debt = 45.7k% (Interest Expense 2.85b / Debt 6.24m)
Taxrate = 41.18% (6.87m / 16.7m)
NOPAT = 19.3m (EBIT 32.9m * (1 - 41.18%))
Current Ratio = 1.67 (Total Current Assets 970.9m / Total Current Liabilities 582.9m)
Debt / Equity = 0.01 (Debt 6.24m / totalStockholderEquity, last quarter 709.1m)
Debt / EBITDA = -10.37 (Net Debt -435.1m / EBITDA 42.0m)
Debt / FCF = -3.97 (Net Debt -435.1m / FCF TTM 109.5m)
Total Stockholder Equity = 671.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.46% (Net Income 18.2m / Total Assets 1.35b)
RoE = 2.70% (Net Income TTM 18.2m / Total Stockholder Equity 671.6m)
RoCE = 4.85% (EBIT 32.9m / Capital Employed (Equity 671.6m + L.T.Debt 6.24m))
RoIC = 2.88% (NOPAT 19.3m / Invested Capital 671.6m)
WACC = 7.94% (E(2.86b)/V(2.86b) * Re(7.96%) + (debt cost/tax rate unavailable))
Discount Rate = 7.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.57%
[DCF Debug] Terminal Value 81.45% ; FCFF base≈103.1m ; Y1≈127.2m ; Y5≈216.6m
Fair Price DCF = 33.65 (EV 3.70b - Net Debt -435.1m = Equity 4.14b / Shares 123.0m; r=7.94% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 39.10 | EPS CAGR: 147.9% | SUE: -0.48 | # QB: 0
Revenue Correlation: 95.96 | Revenue CAGR: 22.00% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.22 | Chg30d=-0.005 | Revisions Net=-2 | Analysts=5
EPS next Year (2026-12-31): EPS=1.05 | Chg30d=-0.006 | Revisions Net=-2 | Growth EPS=+11.2% | Growth Revenue=+10.0%